icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
eNq1mF1v2jAUhu/5FVEudkdCCnSwJVQbazekVmO0aNNukEkOxdTYqT8o7NfPIXSlk7N2Bl/Gdl4f+xw/fuX4bL0k3gq4wIwmfhQ0fA9oyjJMbxN/fHNR7/hnvVq8QCu0N+xt0AiiE99LCRIi8YveYAqIiuDH1eUn0P8D93s1L2bTBaTy2TglMQm+IDG/QnkxxotXDGfeEuScZYmfK7lt9WIhuY6i98D4nchRCnG4a9nvXUxa++1xWIi9QlUJ4JeI3hpFgVpppopzoLKPJNwyvqmIt2mljcUIBFM8hSGS8yFnK5xBZpxihogAq0lmD9k18BUBWUxiFA8X6VJYiaMFWo/gfmAO+oPu7cu1rDfq0dv2abfT6p50O5FdcvneVpmzoBcRppOo2WpGzdMQaHiHyCbThWuZnCHjEhFHacGi/7yyHM3D4f7F9GdY5ARtgoXIbbcKcaS7gevz724hxQpuuCYS0Xv2lz5VhIT/GfV4xwtHERc46jNFZQU2Lka2G9FnVMK6OqN2pJPrXS1iEMeT/cWomfJDNSU4tWWapo4CIcejQTXSjkqDj0jAmLvDwXdMM/Ygjo+Z/bQ6ij7fktIomvMsmmjqn0bttvUp+qlrqOKOOVec5RBqAGFxCFcGdMYOJYouS7PUY1Eerx63VoeliECF2alb0kUX4qM3c1bq7o5R2WEU/Xx+Y1sf3xTwzfX20yiNs+RPZu3Q64LnuhpfCrw8t0k+aTbanW6z9QYt8/ePLjqxdMylqBPDrLgZMnMpc/EuDOdI1AXSexnM+D9ugDPjuo+xdo3bp1S6M/RO7v/SD5WodRT6tLxDX59D2xP7kjs41PHu/t85a+Mckis4IA8l3J0heHB+fKo/2V1nYQ+fscXdNFtriiRm1JVjUlOj4mH3iM4rveAaDl9nM1zxuFJZl3FYPuz0anFYPOr0ar8BM1f+iA==
mFn77GXQm1x8T8J8
Listen
